Alto Neuroscience (NYSE: ANRO) reported a quarterly loss of $(0.65) per share for the quarter ended June 30, 2026, beating the analyst consensus estimate of $(0.73) by 10.96%. The loss per share remained unchanged from the same period last year. In a separate corporate development, the company completed an underwritten registered direct offering in July 2026, raising gross proceeds of approximately $100.0 million and net proceeds of approximately $94.6 million. Giving effect to these proceeds, Alto’s pro forma cash position stands at approximately $338 million, expected to fund planned operations through 2030.

What the Numbers Show

The company’s ability to report a narrower loss than anticipated suggests better-than-expected cost management or operational performance for the quarter, despite the continued unprofitability. The year-over-year stability in the loss per share indicates consistent financial positioning relative to the prior year period. However, total operating expenses rose significantly, driven by increased research and development spending as the company advances its clinical pipeline.

Financial Performance

For the second quarter of 2026, Alto incurred a net loss of $27.6 million, compared to a net loss of $17.7 million in the same period in 2025. This increase was primarily driven by higher operating expenses. Research and development expenses rose to $22.1 million from $13.1 million year-over-year, reflecting accelerated clinical development activities. General and administrative expenses also increased to $7.0 million from $5.6 million.

As of June 30, 2026, the company held cash, cash equivalents, and restricted cash of approximately $244.2 million, up from approximately $177.0 million as of December 31, 2025. The July 2026 capital raise strengthens the balance sheet ahead of key clinical milestones.

Pipeline and Business Highlights

Alto highlighted progress across its clinical-stage pipeline, particularly for its lead candidate ALTO-207, a fixed-dose combination designed to treat treatment-resistant depression (TRD).

• ALTO-207 Development: The company announced plans to add a Phase 3 monotherapy trial for ALTO-207 in TRD, alongside the ongoing potentially registrational Phase 2b adjunctive trial (PACE-1). Topline data for PACE-1 is expected in 2H 2027. The Phase 3 adjunctive trial (PACE-2) is on track to initiate by early 2027, while the new Phase 3 monotherapy trial (PACE-3) is expected to initiate in 2H 2027.
• Clinical Data: Results from the independent PRIME-PRAXOL study, published in Nature Medicine, reinforced the dopaminergic mechanism underlying ALTO-207. The study showed significant effects on anhedonia (Hedges’ g=0.62, p=0.006). The publication also highlighted the tolerability challenges of pramipexole alone, which ALTO-207 aims to mitigate.
• Other Candidates: Enrollment remains ongoing in Phase 2b trials for ALTO-300 in major depressive disorder (MDD) and ALTO-100 in bipolar depression (BPD). Topline data are expected in 1H 2027 for ALTO-300 and mid-2027 for ALTO-100.

Corporate Updates

In June 2026, Alto was added to the Russell 2000 Index and the broad-market Russell 3000 Index. In May 2026, the company appointed Andrew Miller, Ph.D., founder of Karuna Therapeutics, to its Board of Directors. Alto expects patent coverage for ALTO-207 through at least the mid-2040s.

Alto Neuroscience, Inc. has priced an underwritten registered direct offering of 3,776,436 shares of its common stock at $26.48 per share to raise approximately $100.0 million in gross proceeds. The offering is expected to close on July 14, 2026, subject to customary closing conditions. This capital raise is designed to support the acceleration and expansion of the clinical development of ALTO-207, including an additional planned Phase 3 trial as monotherapy for treatment-resistant depression.

As of June 30, 2026, Alto Neuroscience estimates that its cash, cash equivalents, and restricted cash totaled approximately $244.2 million. These preliminary figures have not been audited, reviewed, or compiled by the Company’s independent registered public accounting firm, and actual results may differ materially after comprehensive accounting procedures are completed for the quarter. The financing was led by EcoR1 Capital, with participation from new and existing healthcare-focused investors.

Offering and Cash Position Details

The securities are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-284667), declared effective by the Securities and Exchange Commission (SEC) on February 11, 2025. BofA Securities, Stifel, William Blair, and Baird are acting as the joint book-running managers, with JonesTrading Institutional Services serving as co-manager.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on leveraging neurobiology to develop personalized treatment options. Its pipeline includes seven clinical-stage assets addressing therapeutic areas such as major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson’s disease.